Delmar pharmaceuticals, inc. (DMPI)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10
Expenses
Research and development

898

712

721

-6,364

735

947

1,019

-12,989

1,779

2,141

1,934

-7,943

1,086

1,120

732

2,758

-790

789

603

1,973

641

612

-671

1,611

-618

-566

-560

584

631

333

229

733

254

-

-

-

-

-

-

General and administrative

1,077

1,053

913

-7,533

935

874

986

-6,953

1,155

1,011

744

-5,903

698

571

1,316

2,118

-630

890

474

1,456

500

656

-445

2,723

-966

-636

-741

1,654

920

373

218

394

167

-

3

-

-

-

-

Revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

0

0

0

0

-

Marketing

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

Professional Fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

-

5

-3

6

3

0

0

13

6

Consulting Fee

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

Other Selling General and Administrative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

1

4

0

6

3

1

-

Operating expenses

1,976

1,765

1,635

-13,897

1,671

1,822

2,005

-19,942

2,934

3,153

2,679

-13,846

1,784

1,692

2,049

4,876

-1,420

1,679

1,077

3,430

1,142

1,268

-1,116

4,335

-1,585

-1,202

-1,301

2,238

1,552

3

448

1,127

422

10

-

6

-

-

-

Other (income) loss
Change in fair value of derivative liability

-

-

-

-434

-0

1

-0

-117

2

-0

56

-304

-77

361

-225

2,477

-276

680

-539

-46

-781

892

562

-1,765

1,599

-372

-8,094

-4,599

-2,543

-

0

0

-

-

-

-

-

-

-

Loss on exchange of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-156

-92

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liability due to change in warrant terms

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on exchange of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of shares to Valent for future royalty reduction

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

598

-

0

0

-

-

-

-

-

-

-

Derivative issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

2,713

-

0

0

-

-

-

-

-

-

-

Foreign exchange (gain) loss

2

-2

0

34

-5

-5

-5

114

-6

-7

-43

21

-6

8

-15

-

-10

44

17

-11

-6

-7

2

-2

11

34

-2

25

3

-8

22

-7

12

-

-

-

-

-

-

Change in fair value of derivative liability due to change in warrant terms

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-67

-7

-242

21

-334

0

143

167

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

16

28

28

-110

13

16

19

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

5

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4

0

0

-2

6

-2

-2

-2

1

1

1

1

1

1

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

0

0

0

0

0

-0

1

-0

-0

-0

1

0

-

0

0

-

-

-

-

-

-

-

Other (income) loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-280

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net and comprehensive loss for the period

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,140

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other loss (income)

19

25

29

-383

7

12

13

-43

1

-7

12

-284

-84

370

-240

-

-

966

-543

272

-944

648

400

-1,661

1,612

-336

-8,095

-4,574

-5,852

283

20

-9

10

-

-

-

-

-

-

Weighted average number of shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

30,974

24,316

3,944

-

14,321

12,561

3,944

5,950

-

-

-

-

Total Expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

-

-

Total Expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

14

7

Operating Loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3

-

-0

-3

-10

-3

-6

-3

-14

-7

Net loss for the period

-1,956

-1,740

-1,605

13,513

-1,663

-1,809

-1,991

19,899

-2,933

-3,161

-2,666

13,562

-1,868

-1,321

-2,290

-

-

-

-

-

-

-

-

-

-

-12,722

6,794

-6,813

-7,405

-3

-427

-1,137

-411

-10

-3

-6

-3

-14

-7

Computation of basic loss per share
Net and comprehensive loss for the year

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,290

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Currency translation adjustment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

0

0

-0

-0

-0

Comprehensive Loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3

-

-

-

-10

-

-

-

-14

-7

Comprehensive Loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6

-

-

-

Comprehensive Loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3

-

-

-

-

Comprehensive Loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3

-

-

Basic and fully diluted loss per share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.10

0.24

-

-

-

-

-

-

-

-

-

-0.22

-0.30

0.00

-

-0.08

-0.03

0.00

0.00

0.00

0.00

-

0.00

Net loss for the period

-1,956

-1,740

-1,605

13,513

-1,663

-1,809

-1,991

19,899

-2,933

-3,161

-2,666

13,562

-1,868

-1,321

-2,290

-

-

-

-

-

-

-

-

-

-

865

-6,794

-6,813

-7,405

-3

-427

-1,137

-411

-10

-3

-6

-3

-14

-7

Series B Preferred stock dividend

1

2

2

-155

23

16

36

-318

46

54

41

-852

209

159

-307

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Recapitalization loss on reverse acquisition

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

0

-

-

-

-

-

-

-

Net loss and recapitalization loss on reverse acquisition, total

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,813

-

-

427

1,137

411

-

-

-

-

-

-

Translation to US dollar presentation currency

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

15

-24

-7

-3

-

-

-

-

-

-

Net and comprehensive loss for the period

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,140

2,646

-1,621

-3,158

-2,086

-619

1,516

-5,997

3,198

-865

6,794

-6,813

-7,405

-407

-452

-1,145

-415

-

-

-

-

-

-

Net and comprehensive loss for the period

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,140

2,646

-1,621

-3,158

-2,086

-619

1,516

-5,997

3,198

-865

6,794

-6,813

-7,405

-407

-452

-1,145

-415

-

-

-

-

-

-

Series B Preferred stock dividend

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss for the period attributable to common stockholders

-1,958

-1,742

-1,607

13,669

-1,687

-1,825

-2,027

20,217

-2,979

-3,215

-2,708

9,834

-2,078

-1,481

2,597

6,937

1,140

2,646

-1,621

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and fully diluted loss per share

0.17

0.15

0.21

0.86

0.67

0.75

0.88

3.79

1.31

0.14

0.18

0.20

0.18

0.13

0.23

-

-

-

0.15

0.35

0.05

0.02

0.04

-0.11

0.10

0.03

-0.22

-

-

-

-0.03

-

-

-

-

-

-

-

-

Diluted loss (income) per share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.11

0.10

0.03

-0.02

-

-

-

-0.03

-

-

-

-

-

-

-

-

Net Income (Loss) per share, basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.00

-

Basic and fully diluted number of shares

11,417

11,407

7,538

3,059

2,518

2,424

2,296

-31,790

2,283

22,559

15,292

13,887

11,574

11,424

11,301

11,101

11,077

10,994

10,620

-75,158

38,976

37,798

36,451

33,264

31,659

31,523

31,430

-

-

-

12,969

-

-

-

-

5,950

5,950

2,000

5,950

Diluted weighted average number of shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

51,506

31,659

31,523

41,671

-

-

-

12,969

-

-

-

-

-

-

-

-